


PHARMACEUTICAL 2018

ELI LILLY & Co Rank 212 of 342









ELI LILLY & Co Rank 212 of 342



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 70% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 5.4% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	19,202,100
Cost of Goods Sold	0
Intangible Assets	8,399,300
Liabilities, Current	14,535,900
Liabilities, Non-Current	18,777,200
Other Assets	8,553,100
Other Compr. Net Income	174,500
Other Expenses	11,205,500
Other Liabilities	0
Other Net Income	0
Other Revenues	22,871,300
Property and Equipment	8,826,500
Research and Development	5,281,800
Selling, General and Administrative Expense	6,588,100

Output Variable	Value in 1000 USD
Assets	44,981,000
Liabilities	33,313,100
Expenses	23,075,400
Revenues	22,871,300
Stockholders Equity	11,667,900
Net Income	-204,100
Comprehensive Net Income	-116,850
Economic Capital Ratio	51%

